



Chief Executive: Joe Harrison

Chairman: Simon Lloyd

FOI Request for the Number of Patients Treated

1. Please complete the number of patients treated with Synagis (palivizumab) in the grid below. Please note that the total number of patients (A to E) in each column must add to total patients in the last row in the corresponding column.

Patients / babies treated with Synagis in the last three years		Total number patients treated with Synagis (Palivizumab) April 2018 to March 2019	Total number patients treated with Synagis (Palivizumab) <u>April 2017 to March 2018</u>	Total number patients treated with Synagis (Palivizumab) <u>April 2016 to March 2017</u>
A.	Total number of patients with BPD / CLD diagnosis	10	11	The Trust does not hold this data
B.	Total number of patients with CHD diagnosis	11	15	The Trust does not hold this data
C.	Total number of <29wga (without BPD/CHD diagnosis)	9	32	32
D.	Total number of multiple births immunised (without BPD/CHD diagnosis)	The Trust does not hold this data	The Trust does not hold this data	The Trust does not hold this data
Е.	Other patients (please specify:			
Total number of patients ¹		30 SUP	58	32

BPD: bronchopulmonary dysplasia; CLD: Chronic Lung Disease; CHD: congenital heart disease

2. Please advise which OPCS codes are used within your Trust to code respiratory syncytial virus (RSV)

Code Description	Used within Trust to indicate patient received RSV prophylaxis treatment? Yes/No		
X86.5 Respiratory syncytial virus prevention drugs band 1	Yes		
X44.2 Intramuscular injection of vaccine	Yes		
Other (if not listed above, please specify code(s)):			

3. If your Trust does not provide RSV prophylaxis treatment and you refer your patients to another Trust, please state to which Trust(s) patients are referred.

Total patients treated with Synagis in each of the last 3 years: 120